{"id":177,"date":"2026-07-13T10:19:14","date_gmt":"2026-07-13T08:19:14","guid":{"rendered":"https:\/\/pharmatek.cc\/?post_type=product&p=177"},"modified":"2026-09-01T20:12:37","modified_gmt":"2026-09-01T18:12:37","slug":"retartutide-pen","status":"publish","type":"product","link":"https:\/\/pharmatek.cc\/es\/producto\/retartutide-pen\/","title":{"rendered":"RETATRUTIDE PEN"},"content":{"rendered":"

Retatrutide Pen de Pharmatek representa el m\u00e1ximo avance farmacol\u00f3gico en el tratamiento metab\u00f3lico y la recomposici\u00f3n corporal. Al actuar simult\u00e1neamente sobre los tres receptores clave del metabolismo (GIP, GLP-1 y Glucag\u00f3n), esta mol\u00e9cula no solo regula la secreci\u00f3n de insulina y ralentiza el vaciado g\u00e1strico, sino que incrementa de forma activa la termog\u00e9nesis y la oxidaci\u00f3n de \u00e1cidos grasos a nivel hep\u00e1tico y adiposo.<\/p>\n

Presentado en un formato de pluma autoinyectora ergon\u00f3mica de dosis ajustable, Retatrutide Pen garantiza una administraci\u00f3n limpia, indolora y exacta, eliminando la necesidad de reconstituci\u00f3n manual. Su dise\u00f1o preconfigurado est\u00e1 concebido para optimizar la adherencia al tratamiento con la m\u00e1xima seguridad biol\u00f3gica.<\/p>\n

    \n
  1. Ficha T\u00e9cnica<\/strong><\/li>\n<\/ol>\n
      \n
    • Nombre Comercial: <\/strong>Retatrutide Pen Pharmatek.<\/li>\n
    • Principio Activo: <\/strong>Retatrutide (Triple Agonista de receptores GIP \/ GLP-1 \/ Glucag\u00f3n).<\/li>\n
    • Presentaci\u00f3n: <\/strong>Pluma autoinyectora precargada multidosis \/ cartucho de soluci\u00f3n lista para usar.<\/li>\n
    • V\u00eda de Administraci\u00f3n: <\/strong>Inyecci\u00f3n subcut\u00e1nea (S.C.) semanal.<\/li>\n<\/ul>\n
        \n
      1. Composici\u00f3n<\/strong><\/li>\n<\/ol>\n

        Cada pluma precargada contiene:<\/em><\/p>\n

          \n
        • Retatrutide en soluci\u00f3n: <\/strong>Concentraci\u00f3n de grado farmac\u00e9utico estabilizada.<\/li>\n
        • Excipientes: <\/strong>Fosfato de sodio, fenol, cloruro de sodio y agua para inyecci\u00f3n (c.s.p.).<\/li>\n<\/ul>\n
            \n
          1. Propiedades y Beneficios<\/strong><\/li>\n<\/ol>\n
              \n
            • Mecanismo Triple Agonista: <\/strong>Activaci\u00f3n simult\u00e1nea de receptores GIP, GLP-1 y Glucag\u00f3n para una efectividad metab\u00f3lica superior.<\/li>\n
            • Gasto Energ\u00e9tico Aumentado: <\/strong>El componente de glucag\u00f3n eleva la tasa metab\u00f3lica basal y promueve la lip\u00f3locis directa.<\/li>\n
            • Formato Pen Ergon\u00f3mico: <\/strong>Sistema de marcaci\u00f3n dial-a-dose que asegura la dosificaci\u00f3n exacta con agujas microfina.<\/li>\n
            • Control del Apetito Avanzado: <\/strong>Inhibe eficazmente la saciedad a nivel central y retrasa el vaciado g\u00e1strico.<\/li>\n<\/ul>\n
                \n
              1. Modo de Uso y Conservaci\u00f3n<\/strong><\/li>\n<\/ol>\n
                  \n
                • Administraci\u00f3n: <\/strong>Inyectar por v\u00eda subcut\u00e1nea una vez por semana en el abdomen, muslo o parte posterior del brazo.<\/li>\n
                • Conservaci\u00f3n (Sin abrir): <\/strong>Refrigerar entre 2\u00b0C y 8\u00b0C (36\u00b0F a 46\u00b0F). No congelar.<\/li>\n
                • Conservaci\u00f3n (En uso): <\/strong>Puede mantenerse a temperatura ambiente (<25\u00b0C) o refrigerado por hasta 30 d\u00edas protegido de la luz.<\/li>\n<\/ul>\n
                    \n
                  1. Advertencias<\/strong><\/li>\n<\/ol>\n
                      \n
                    • Uso Bajo Supervisi\u00f3n: <\/strong>Producto de alta potencia metab\u00f3lica. Utilizar bajo protocolo supervisado.<\/li>\n
                    • Titulaci\u00f3n Gradual: <\/strong>Se recomienda comenzar con dosis bajas e incrementar paulatinamente para minimizar efectos gastrointestinales.<\/li>\n
                    • Contraindicaciones: <\/strong>No administrar en pacientes con antecedentes personales o familiares de carcinoma medular de tiroides o s\u00edndrome NEM 2.<\/li>\n
                    • Efectos secundarios: <\/strong>Posibles n\u00e1useas, heces blandas o leve taquicardia transitoria debido a la estimulaci\u00f3n del glucag\u00f3n.<\/li>\n
                    • Seguridad Infantil: <\/strong>Mantener fuera del alcance de los ni\u00f1os.<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"

                      Retatrutide Pen by Pharmatek <\/strong>is a next-generation prefilled autoinjector pen harnessing triple receptor agonist technology (GIP, GLP-1, and Glucagon). Engineered for maximum dosing accuracy and convenience in metabolic regulation protocols, it synergistically drives lipolysis, appetite suppression, and elevated energy expenditure.<\/p>","protected":false},"featured_media":237,"template":"","meta":{"_uag_custom_page_level_css":""},"product_brand":[],"product_cat":[20],"product_tag":[],"class_list":["post-177","product","type-product","status-publish","has-post-thumbnail","product_cat-pectides","first","instock","shipping-taxable","product-type-simple"],"uagb_featured_image_src":{"full":["https:\/\/pharmatek.cc\/wp-content\/uploads\/2026\/07\/RETATRUTIDE-PEN.webp",1195,896,false],"thumbnail":["https:\/\/pharmatek.cc\/wp-content\/uploads\/2026\/07\/RETATRUTIDE-PEN-150x150.webp",150,150,true],"medium":["https:\/\/pharmatek.cc\/wp-content\/uploads\/2026\/07\/RETATRUTIDE-PEN-300x225.webp",300,225,true],"medium_large":["https:\/\/pharmatek.cc\/wp-content\/uploads\/2026\/07\/RETATRUTIDE-PEN-768x576.webp",768,576,true],"large":["https:\/\/pharmatek.cc\/wp-content\/uploads\/2026\/07\/RETATRUTIDE-PEN-1024x768.webp",1024,768,true],"1536x1536":["https:\/\/pharmatek.cc\/wp-content\/uploads\/2026\/07\/RETATRUTIDE-PEN.webp",1195,896,false],"2048x2048":["https:\/\/pharmatek.cc\/wp-content\/uploads\/2026\/07\/RETATRUTIDE-PEN.webp",1195,896,false],"trp-custom-language-flag":["https:\/\/pharmatek.cc\/wp-content\/uploads\/2026\/07\/RETATRUTIDE-PEN-16x12.webp",16,12,true],"woocommerce_thumbnail":["https:\/\/pharmatek.cc\/wp-content\/uploads\/2026\/07\/RETATRUTIDE-PEN-300x300.webp",300,300,true],"woocommerce_single":["https:\/\/pharmatek.cc\/wp-content\/uploads\/2026\/07\/RETATRUTIDE-PEN-600x450.webp",600,450,true],"woocommerce_gallery_thumbnail":["https:\/\/pharmatek.cc\/wp-content\/uploads\/2026\/07\/RETATRUTIDE-PEN-100x100.webp",100,100,true]},"uagb_author_info":{"display_name":"Admin","author_link":"https:\/\/pharmatek.cc\/es\/author\/"},"uagb_comment_info":0,"uagb_excerpt":"Retatrutide Pen by Pharmatek is a next-generation prefilled autoinjector pen harnessing triple receptor agonist technology (GIP, GLP-1, and Glucagon). Engineered for maximum dosing accuracy and convenience in metabolic regulation protocols, it synergistically drives lipolysis, appetite suppression, and elevated energy expenditure.","_links":{"self":[{"href":"https:\/\/pharmatek.cc\/es\/wp-json\/wp\/v2\/product\/177","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharmatek.cc\/es\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/pharmatek.cc\/es\/wp-json\/wp\/v2\/types\/product"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmatek.cc\/es\/wp-json\/wp\/v2\/media\/237"}],"wp:attachment":[{"href":"https:\/\/pharmatek.cc\/es\/wp-json\/wp\/v2\/media?parent=177"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/pharmatek.cc\/es\/wp-json\/wp\/v2\/product_brand?post=177"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/pharmatek.cc\/es\/wp-json\/wp\/v2\/product_cat?post=177"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/pharmatek.cc\/es\/wp-json\/wp\/v2\/product_tag?post=177"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}